Literature DB >> 17209221

Approach to the patient with subclinical hyperthyroidism.

David S Cooper1.   

Abstract

Endogenous subclinical hyperthyroidism, defined by normal circulating levels of free T4 and T3 and low levels of TSH, is a common clinical entity and is typically caused by the same conditions that account for the majority of cases of overt hyperthyroidism: Graves' disease, toxic multinodular goiter, and solitary autonomously functioning thyroid nodules. Subclinical hyperthyroidism has been associated with an increased risk of atrial fibrillation and mortality, decreased bone mineral density in postmenopausal women, and mild hyperthyroid symptoms. Treatment of subclinical hyperthyroidism remains controversial, given the lack of prospective randomized controlled trials showing clinical benefit with restoration of the euthyroid state. Nevertheless, it seems reasonable to treat older individuals whose serum TSH levels are less than 0.1 mU/liter and certain high-risk patients, even when the serum TSH is between 0.1 and the lower limit of the normal range.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17209221     DOI: 10.1210/jc.2006-2472

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Approach to and treatment of thyroid disorders in the elderly.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Med Clin North Am       Date:  2012-02-14       Impact factor: 5.456

2.  Dose optimization of lithium to increase the uptake and retention of I-131 in rat thyroid.

Authors:  Sanny B Kumar; Rozy Kamal; Anna Khan; Vijayta D Chadha
Journal:  Radiat Environ Biophys       Date:  2019-02-27       Impact factor: 1.925

3.  Subclinical hyperthyroidism and sport eligibility: an exploratory study on cardiovascular pre-participation screening in subjects treated with levothyroxine for multinodular goiter.

Authors:  L Di Luigi; A Parisi; F Quaranta; F Romanelli; E Tranchita; P Sgrò; P Nardi; G Fattorini; R Cavaliere; F Pigozzi; M D'Armiento; A Lenzi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

4.  The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.

Authors:  Bernadette Biondi; Luigi Bartalena; David S Cooper; Laszlo Hegedüs; Peter Laurberg; George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-08-26

5.  Effects of thyroid dysfunction on lipid profile.

Authors:  C V Rizos; M S Elisaf; E N Liberopoulos
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

6.  Efficacy of Low-dose (2 millicurie) versus Standard-dose (4 millicurie) Radioiodine Treatment for Cats with Mild-to-Moderate Hyperthyroidism.

Authors:  J M Lucy; M E Peterson; J F Randolph; P V Scrivani; M Rishniw; D L Davignon; M S Thompson; J M Scarlett
Journal:  J Vet Intern Med       Date:  2017-02-03       Impact factor: 3.333

7.  Management of subclinical hyperthyroidism.

Authors:  Silvia Santos Palacios; Eider Pascual-Corrales; Juan Carlos Galofre
Journal:  Int J Endocrinol Metab       Date:  2012-04-20

8.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.